Good morning, everyone, and welcome to the middle of the week, which arrived rather quickly, no? Well, congratulations are in order for getting this far, so please join us as we fire up the coffee kettle and celebrate with a cup of stimulation. We look for any excuse we can get, as you probably know. Meanwhile, we have assembled a few items of interest to go with that cup of stimulation. Hope your day is smashing and, as always, please do keep in touch. We appreciate cards, emails, and secret dossiers.

President Trump’s brief remarks on drug pricing during the State of the Union address appeared uncontroversial as he urged Congress to pass a bipartisan drug pricing bill, STAT says. Democrats, however, came armed with a surprisingly strong response: From the back of the House chamber, dozens of lawmakers stood, held up three fingers, and unleashed a three-syllable chant: “H.R. 3.” They were touting House Resolution 3, the aggressive bill Democrats passed in December that would allow Medicare to directly negotiate the price of up to 250 drugs.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy